397 related articles for article (PubMed ID: 11685722)
21. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
Nehmé A; Varadarajan P; Sellakumar G; Gerhold M; Niedner H; Zhang Q; Lin X; Christen RD
Br J Cancer; 2001 Jun; 84(11):1571-6. PubMed ID: 11384110
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
23. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Li Y; Okegawa T; Lombardi DP; Frenkel EP; Hsieh JT
J Urol; 2002 Jan; 167(1):339-46. PubMed ID: 11743353
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.
Kraus LA; Samuel SK; Schmid SM; Dykes DJ; Waud WR; Bissery MC
Invest New Drugs; 2003 Aug; 21(3):259-68. PubMed ID: 14578676
[TBL] [Abstract][Full Text] [Related]
25. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
26. Signal transduction pathways of taxanes-induced apoptosis.
Ganansia-Leymarie V; Bischoff P; Bergerat JP; Holl V
Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):291-306. PubMed ID: 12769774
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Georgoulias V
Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
[TBL] [Abstract][Full Text] [Related]
28. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
Leung SY; Jackson J; Miyake H; Burt H; Gleave ME
Prostate; 2000 Jul; 44(2):156-63. PubMed ID: 10881025
[TBL] [Abstract][Full Text] [Related]
29. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Tolcher AW
Semin Oncol; 2001 Aug; 28(4 Suppl 15):67-70. PubMed ID: 11685732
[TBL] [Abstract][Full Text] [Related]
30. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Beer TM; Hough KM; Garzotto M; Lowe BA; Henner WD
Semin Oncol; 2001 Aug; 28(4 Suppl 15):49-55. PubMed ID: 11685729
[TBL] [Abstract][Full Text] [Related]
31. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for androgen-independent prostate cancer.
Petrylak DP
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):31-5. PubMed ID: 12198636
[TBL] [Abstract][Full Text] [Related]
33. [Chemotherapy of prostate cancer: potential role of docetaxel].
Bracarda S
Tumori; 2001; 87(6):A12-4. PubMed ID: 11995697
[No Abstract] [Full Text] [Related]
34. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Miayake H; Tolcher A; Gleave ME
J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel (Taxotere): preclinical and general clinical information.
Earhart RH
Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
37. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Williams JF; Muenchen HJ; Kamradt JM; Korenchuk S; Pienta KJ
Prostate; 2000 Sep; 44(4):275-8. PubMed ID: 10951491
[TBL] [Abstract][Full Text] [Related]
38. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
